4 Stocks Pushing The Health Care Sector Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 35 points (0.3%) at 14,006 as of Tuesday, Feb. 12, 2013, 12:05 PM ET. The NYSE advances/declines ratio sits at 1,786 issues advancing vs. 1,060 declining with 154 unchanged.

The Health Care sector currently sits up 0.2% versus the S&P 500, which is up 0.1%.

TheStreet Ratings group would like to highlight 4 stocks pushing the sector higher today:

4. Brookdale Senior Living ( BKD) is one of the companies pushing the Health Care sector higher today. As of noon trading, Brookdale Senior Living is up $1.54 (5.7%) to $28.42 on heavy volume Thus far, 1.5 million shares of Brookdale Senior Living exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $27.45-$28.67 after having opened the day at $28.04 as compared to the previous trading day's close of $26.88.

Brookdale Senior Living Inc. owns and operates senior living communities in the United States. The company owns, leases, and operates retirement centers, assisted living and dementia-care communities, and continuing care retirement communities (CCRCs). Brookdale Senior Living has a market cap of $3.4 billion and is part of the health services industry. Shares are up 8.2% year to date as of the close of trading on Monday. Currently there are 7 analysts that rate Brookdale Senior Living a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Brookdale Senior Living as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, generally higher debt management risk and poor profit margins. Get the full Brookdale Senior Living Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

3. As of noon trading, Novo Nordisk A/S ( NVO) is up $3.06 (1.8%) to $168.46 on heavy volume Thus far, 476,065 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 253,500 shares. The stock has ranged in price between $167.62-$168.70 after having opened the day at $167.93 as compared to the previous trading day's close of $165.40.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. The company operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $107.7 billion and is part of the drugs industry. The company has a P/E ratio of 4.0, below the S&P 500 P/E ratio of 17.7. Shares are up 17.8% year to date as of the close of trading on Monday. Currently there are 2 analysts that rate Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novo Nordisk A/S Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

2. As of noon trading, Sanofi ( SNY) is up $0.76 (1.6%) to $48.77 on heavy volume Thus far, 2.4 million shares of Sanofi exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $48.08-$48.85 after having opened the day at $48.13 as compared to the previous trading day's close of $48.01.

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. Sanofi has a market cap of $123.0 billion and is part of the drugs industry. The company has a P/E ratio of 25.0, above the S&P 500 P/E ratio of 17.7. Shares are down 1.8% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate Sanofi a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

1. As of noon trading, Biogen Idec ( BIIB) is up $0.93 (0.6%) to $164.89 on light volume Thus far, 332,711 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $163.32-$165.00 after having opened the day at $163.98 as compared to the previous trading day's close of $163.96.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $38.9 billion and is part of the drugs industry. The company has a P/E ratio of 28.5, above the S&P 500 P/E ratio of 17.7. Shares are up 12.3% year to date as of the close of trading on Monday. Currently there are 11 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Biogen Idec Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

The Astonishing Return Of Steven Cohen

The Astonishing Return Of Steven Cohen

These Stocks Are Ready to Reverse Course

These Stocks Are Ready to Reverse Course

The 10% Pop in H&R Block Has Nothing to Do With the Fed

The 10% Pop in H&R Block Has Nothing to Do With the Fed

Fed Has Nothing to Do With the 10% Pop in H&R Block

Fed Has Nothing to Do With the 10% Pop in H&R Block

Analysts' Actions -- Adobe, Starbucks, Snap, KB Home and More

Analysts' Actions -- Adobe, Starbucks, Snap, KB Home and More